Previous 10 | Next 10 |
2023-08-30 09:20:30 ET Summary PMV Pharmaceuticals is closing in on updated results from a phase 1/2 study of PC14586, a p53 reactivator with potential in various cancer types. The company plans to start phase 2 work in early 2024, having already engaged in end of phase 1 talks wi...
2023-08-10 13:59:57 ET PMV Pharmaceuticals press release ( NASDAQ: PMVP ): Q2 GAAP EPS of -$0.38. PMV Pharma ended the second quarter with $218.8 million in cash, cash equivalents, and marketable securities, compared to $277.4 million as of June 30...
2023-08-09 18:20:52 ET Gainers: Applovin Corporation ( APP ) +23% . Alarm.com Holdings ( ALRM ) +13% . PMV Pharmaceuticals ( PMVP ) +11% . Digital World Acquisition ( DWAC ) +10% . Sonos ( SONO ) +9% . Losers: SunOp...
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; updated Phase 1 data expected in 2H 2023 Concluded successful End-of-Phase 1 FDA meeting with alignm...
2023-07-07 17:29:48 ET Gainers: Black Diamond Therapeutics ( NASDAQ: BDTX ) +9% . CareMax ( CMAX ) +5% . Outbrain ( OB ) +5% . Sientra ( SIEN ) +4% . iHeartMedia ( IHRT ) +4% . Losers: CRISPR Therapeutics ( CR...
2023-05-15 08:03:39 ET Summary PMV Pharmaceuticals has very interesting science. PMVP's drug seems to be active in activating p53. However, the toxicity profile may be unacceptable. PMV Pharmaceuticals ( PMVP ) develops small molecule, tumor-agnostic therapies fo...
Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; next update is expected in 2H 2023 Commenced enrollment in the combination arm of the PYNNACLE s...
2023-03-27 09:48:13 ET As Wall Street approaches the end of the first quarter, the major U.S. equity averages are trading higher for 2023 so far, despite the turmoil caused by the bank crisis. Still, many traders have made large bets against a handful of well-known names, including Silv...
PMV Pharmaceuticals press release ( NASDAQ: PMVP ): FY GAAP EPS of -$1.61 beats by $0.03 . Cash, cash equivalents, and marketable securities of $243.5 million as of December 31, 2022 For further details see: PMV Pharmaceuticals GAAP EPS of -$1.61 beats by $0.03
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in 2H 2023 Enrolled first patient in combination arm of ...
News, Short Squeeze, Breakout and More Instantly...
PMV Pharmaceuticals Inc. Company Name:
PMVP Stock Symbol:
NASDAQ Market:
PMV Pharmaceuticals Inc. Website:
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Off...
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOn...
2024-05-13 08:30:02 ET Craig-Hallum analyst issues BUY recommendation for PMVP on May 13, 2024 07:30AM ET. PMVP was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recommendations...